HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) All Versions of this Article: clinchem.2009.127308v1 55/7/1268    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Google Scholar Articles by Kågedal, B. PubMed PubMed Citation Articles by Kågedal, B.

Detecting Minimal Residual Disease in Neuroblastoma: Still a Ways to Go

¹ Department of Clinical Chemistry, University Hospital, Linköping, Sweden.

^aAddress correspondence to the author at: Department of Clinical Chemistry, University Hospital, S-581 85 Linköping, Sweden. Fax +46-13-223240; e-mail bertil.kagedal@lio.se.

The first 300 words of the full text of this article appear below.

Neuroblastoma is the most common extracranial solid tumor of childhood and accounts for 10% of all cancers in children. The development of neuroblastoma involves both embryonic and tumorigenic factors, making the tumor very heterogeneous both biologically and clinically. Neuroblastoma tumors originate from embryonic neural crest cells committed to the development of the sympathetic nervous system, and their malignancy varies from totally benign with spontaneous regression to highly malignant (1). Prognostic factors include age of the patient at diagnosis, INSS (International Neuroblastoma Staging System) stage, tumor histopathology, and ploidy status of DNA content (2). Despite the availability of many clinical and biologic markers proposed as predictive of disease outcome and the use of advanced multimodal therapy, treatment results are still suboptimal for patients with these tumors. Thus, how to best estimate patient prognosis and choose optimal individual therapy remain fundamental challenges.

Since the discovery by Moss et al. (3) 20 years ago of neuroblastoma cells in the blood of a majority of patients with known disseminated disease, much work has been devoted to the development and improvement of methods for detection of minimal residual disease (MRD).¹

In this issue of Clinical Chemistry Stutterheim et al. (4) address the question of how to best identify the presence of neuroblastoma cells in blood and bone marrow by use of reverse transcription quantitative PCR (RQ-PCR). The authors recently investigated the use of paired-like homeobox 2b (PHOX2B)² as a marker for MRD in neuroblastoma and claimed reported that this transcript was the most specific single marker for this purpose (5). In the current study they selected 28 genes from SAGE libraries that showed high expression in neuroblastoma tumors and little or no expression in normal tissues. Preliminary studies of these 28 genes and . . . [Full Text of this Article]